Subsequently, in vitro cytotoxicity ability of shD-NKG2D-CAR-T cells was authenticated in an in vivo setting, where shD-NKG2D-CAR-T cells demonstrated superior anti-tumor efficacy in a prostate cancer xenograft model. This evidence concerns the gene KLRK1 and neoplasm.